Early cancer drug combo trial halted by sponsor
NCT ID NCT04972110
Summary
This study aimed to test the safety and find the right dose of two different oral drug combinations for adults with advanced solid tumors that have specific genetic markers and have stopped responding to standard treatments. The trial was terminated early by the sponsor, so the main expansion phase was not completed. The goal was to see if combining a new drug (camonsertib) with existing cancer drugs (niraparib or olaparib) could help control these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Participating Site # 1001
Houston, Texas, 77030, United States
-
Participating Site # 1008
New York, New York, 10032, United States
-
Participating Site # 1013
Salt Lake City, Utah, 84112, United States
-
Participating Site # 1016
Rochester, Minnesota, 55905, United States
-
Participating Site #1009
Baltimore, Maryland, 21205, United States
-
Participating Site #1012
New Haven, Connecticut, 06511, United States
-
Participating Site #1015
Ann Arbor, Michigan, 48109, United States
-
Participating Site #1017
Jacksonville, Florida, 32224, United States
-
Participating Site #1018
Phoenix, Arizona, 97401, United States
-
Participating Site #1025
San Francisco, California, 94158, United States
-
Participating Site #1026
New York, New York, 10029, United States
-
Participating Site #1028
Aurora, Colorado, 80012, United States
-
Participating Site #1029
Eugene, Oregon, 97401, United States
Conditions
Explore the condition pages connected to this study.